Which Statin Is Right for Me?

Statins are unusual in that the hard part is rarely deciding whether to take one. Once that is settled, the class is large, the members are broadly interchangeable at matched intensity, and the real question becomes which one you will still be taking in a year.

That reframing matters, because the dominant reason people stop is muscle pain, and the statins differ substantially in how likely they are to cause it in a given person. This is one of the cleanest examples in pharmacogenetics of a result that points at a specific alternative within the same class.

This comes first and it sets the intensity rather than the brand. Guidelines think in terms of high, moderate and low intensity, and several statins can reach any given intensity at the appropriate dose. Someone who has already had a heart attack needs a different target from someone being treated on the basis of risk alone, and that target narrows the practical options before anything else is considered.

This is the single most useful piece of history, and it is often not asked about directly. Muscle aching, cramping or weakness, particularly in the large muscles of the thighs and shoulders, is the main reason people discontinue. If a previous statin caused it, that shapes the next choice more than anything else, because the statins are not equally implicated.

Some statins are cleared by enzymes that many common medications inhibit, which can raise statin levels several-fold and with them the risk of muscle injury. Simvastatin and lovastatin are the most exposed to this; pravastatin and rosuvastatin are comparatively insulated. Anyone taking certain antifungals, some antibiotics, or particular heart medications will find that this consideration narrows the field quickly.

Impaired kidney function limits the dose of some statins more than others. Liver disease, significant alcohol use, and hypothyroidism all change the risk calculation. These are ordinary clinical constraints and they take precedence over preference.

Here is where genetics contributes, and unusually for pharmacogenetics it points to a specific action within the class. A transporter called SLCO1B1 moves statins out of the bloodstream and into liver cells, which is both where they work and how they leave circulation.^[1] Reduced transporter function means more statin stays in the blood, and therefore reaches muscle, which is the direct mechanism behind statin-associated muscle symptoms.

Crucially, the statins do not depend on this transporter equally. Simvastatin is the most affected. Others are affected far less. So a reduced-function result is not an argument against statins as a whole; it is an argument for a particular one.

Most statins are inexpensive generics, so cost rarely decides this. Some are best taken in the evening because of when cholesterol synthesis peaks, while others can be taken at any time, and for some people that practical difference is what determines whether the tablet is actually taken.

One transporter gene does most of the work here, with two metabolising genes playing smaller roles for particular members of the class.

The pattern is what makes this class useful to think about genetically. A reduced-function SLCO1B1 result puts simvastatin at the bottom of the list and leaves several alternatives essentially unaffected, so it narrows the choice without limiting your options for treating cholesterol.

It is worth being clear about what the result does not say. It speaks to the risk of muscle symptoms, not to how well the statin will lower your cholesterol. Efficacy is a matter of intensity and dose.

The clearest case is muscle symptoms on a statin, either now or in the past, where an SLCO1B1 result can distinguish between a drug-specific problem with an obvious alternative and a reason to reconsider the class. It is equally useful before starting, particularly if simvastatin is being considered or if you have a family history of statin intolerance.

It is less useful if your issue is that cholesterol is not falling far enough, since that is a question of intensity rather than of transport.

• Muscle Pain From Statins? Genetics May Be the Reason
• 23andMe Drug Response: What You'll Actually See in a Report From Your Data
• Nebula Genomics Drug Response: What You'll Actually See in a Report From Your WGS Data
• Grapefruit Juice and Medications: Why Drug Labels Warn About It
• 23andMe Pharmacogenetics: How to Get a Drug Response Report From Your Existing Data
• AncestryDNA for Drug Testing: Get Pharmacogenetics From Your Ancestry Data

There is no universal answer, but simvastatin is the most strongly associated with muscle symptoms in people with reduced SLCO1B1 transporter function, and pravastatin and rosuvastatin depend on that transporter far less. Which is best for you depends on your transporter status, the intensity you need and your other medications, so it is a conversation to have with your prescriber.

No. It relates to how much statin stays in your bloodstream and therefore to the risk of muscle side effects. How much your cholesterol falls is determined mainly by which statin and what dose, not by this gene.

Usually not. Because the statins vary considerably in how much they depend on the SLCO1B1 transporter, many people who cannot tolerate one do fine on another, sometimes at a lower dose or a less frequent schedule. Abandoning the class altogether is rarely the first step.

It is reasonable, particularly if simvastatin is being considered or if statin intolerance runs in your family. Testing is not required before starting, and many people do perfectly well without it, but it can save a failed trial and the discouragement that follows.